Increased Serum S-TRAIL Level in Newly Diagnosed Stage-IV Lung Adenocarcinoma but not Squamous Cell Carcinoma is Correlated with Age and Smoking

  • Kargi, Aysegul (Division of Medical Oncology, Department of Internal Medicine, Akdeniz University) ;
  • Bisgin, Atil (Division of Oncology, Department of Clinical and Experimental Medicine, University of Linkoping) ;
  • Yalcin, Arzu Didem (Allergy and Clinical Immunology Unit, Antalya Training and Research Hospital, Akdeniz University) ;
  • Kargi, Ahmet Bulent (Department of Thoracic Surgery, Medical Park Hospital, Akdeniz University) ;
  • Sahin, Emel (Department of Biochemistry, Faculty of Medicine, Akdeniz University) ;
  • Gumuslu, Saadet (Department of Biochemistry, Faculty of Medicine, Akdeniz University)
  • Published : 2013.08.30


Background: Lung cancer is the leading cause of cancer mortality in the world. Many factors can protect against or facilitate its development. A TNF family member TRAIL, has a complex physiological role beyond that of merely activating the apoptotic pathway in cancer cells. Vitamin D is converted to its active form locally in the lung, and is also thought to play an important role in lung health. Our goal was to investigate the possible clinical significance of serum sTRAIL and 1,25-dihydroxyvitamin D(3) levels in patients with non-small cell lung cancer (NSCLC). Materials and Methods: Totals of 18 consecutive adenocarcinoma and 22 squamous cell carcinoma patients with stage-IV non-small cell lung cancer referred to our institute were included in this study. There were 12 men and 6 women, with ages ranging from 38 to 97 (mean 60.5) years with adenocarcinoma, and 20 men and 2 women, with ages ranging from 46 to 80 (mean 65) years with squamous cell carcinoma. Serum levels of sTRAIL and 1,25-dihydroxyvitamin D(3) were measured in all samples at the time of diagnosis. Results: sTRAIL levels in NSCLC patients were higher than in the control group. Although there was no correlation between patient survival and sTRAIL levels, the highest sTRAIL levels were correlated with age and cigarette smoking in the adenocarcinoma patients. sTRAIL level in healthy individuals were correlated with serum 1,25-dihydroxyvitamin D(3). Conclusions: Serum sTRAIL concentrations were increased in NSCLC patients, and correlated with age and smoking history, but not with overall survival.


Soluble TRAIL;non-small cell lung cancer;adenocarcinoma;squamous cell carcinoma


  1. Ashkenazi A, Pai RC, Fong S, et al (1999). Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest, 104, 155-62.
  2. Aydin C, Sanlioglu AD, Bisgin A et al (2010). NF-${\kappa}B$ targeting by way of IKK inhibition sensitizes lung cancer cells to adenovirus delivery of TRAIL. BMC Cancer, 10, 584.
  3. Barbone F, Cavallieri F, Stanta G (1997). Cigarette smoking and histological type of lung cancer in men. Chest, 112, 1474-79.
  4. Beumer JH, Parise RA, Kanterewicz B et al (2012). A local effect of CYP24 inhibition on lung tumor xenograft exposure to 1,25-dihydroxyvitamin D(3) is revealed using a novel LC-MS/MS assay. Steroids, (Epub ahead of print).
  5. Bisgin A, Kargi A, Yalcin AD et al (2012a). Increased serum sTRAIL levels were correlated with patient survival in BevacizumAb treated metastatic colon cancer patients. BMC Cancer, 12, 58.
  6. Bisgin A, Yalcin AD, Gorczynski RM. (2012b). Circulating soluble tumor necrosis factor related apoptosis inducing-ligand (TRAIL) is decreased in type-2 newly diagnosed, non-drug using diabetic patients. Diabetes Res Clin Pract, (Epub ahead of print); doi: 10.1016/j.diabres.2012.02.028
  7. Brambilla E, Travis W, Colby T et al (2001). The new World Health Organization classification of lung tumours. Eur J Respir, 18, 1059-68.
  8. Charloux A, Rossignal M, Purohit A et al (1997). International differences in epidemiology of lung carcinoma. Lung Cancer, 16, 133-43.
  9. Curran JN, Garrett-Mayer E, Carpenter MJ et al (2011). Cigarette smoking and the risk of dying from tobacco-related malignancies by race. Anticancer Res, 31, 3891-5.
  10. Deftereos S, Giannopoulos G, Kossyvakis C et al (2012). Association of soluble tumour necrosis factor-related apoptosis-inducing ligand levels with coronary plaque burden and composition. Heart, 98, 214-8.
  11. Griffith TS, Lynch DH (1998). TRAIL: a molecule with multiple receptors and control mechanisms. Curr Opin Immunol, 10, 559-63
  12. Greenlee RT, Murray T, Bolden S et al (2000). Cancer statistics. CA Cancer J Clin, 50, 7-33.
  13. Liabeuf S, Barreto DV, Barreto FC et al (2010). The circulating soluble TRAIL is a negative marker for inflammation inversely associated with the mortality risk in chronic kidney disease patients. Nephrol Dial Transplant, 25, 2596-602.
  14. McGrath EE (2011). The tumor necrosis factor-related apoptosis-inducing ligand and lung cancer: still following the right TRAIL? Review. J Thorac Oncol, 6, 983-7.
  15. Norton R, O’Connell MA (2012). Vitamin D: potential in the prevention and treatment of lung cancer. Anticancer Res, 32, 211-21.
  16. Parkin DM (2001). Global cancer statistics in the year 2000. Lancet Oncol, 2, 533-43.
  17. Parkin DM (2004). International variation. Oncogene, 23, 6329-40.
  18. Pazdiora P, Svobodova S, Fuchsova R et al (2011). Vitamin D in colorectal, breast, prostate and lung cancer: a pilot study. Anticancer Res, 31, 3619-21.
  19. Radzwikowska E, Glaz P, Roszkowski K (2002) Lung cancer in women: age, smoking, histology, performance status, stage, initial treatment and survival: populationbased study of 20,561 cases. Ann Oncol, 13, 1087-93.
  20. Ramnath N, Kim S, Christensen PJ (2011). Vitamin D and lung cancer. Expert Rev Respir Med, 5, 305-9.
  21. Sanlioglu AD, Koksal IT, Karacay B et al (2006). Adenovirus-mediated IKKbetaKA expression sensitizes prostate carcinoma cells to TRAIL-induced apoptosis. Cancer Gene Ther, 13, 21-31.
  22. Schiller JH (2001). Current standards of care in small-cell and non-small-cell lung cancer. Oncol, 61, 3-13.
  23. Spira A, Ettinger DS (2004). Multidisciplinary management of lung cancer. N Engl J Med, 350, 379-92.
  24. Stupp R, Monnerat C, Turrisi AT 3rd et al (2004). Small cell lung cancer: state of the art and future perspectives. Lung Cancer, 45, 105-17.
  25. Terzioglu E, Bisgin A, Sanlioglu AD et al (2007). Concurrent gene therapy strategies effectively destroy synoviocytes of patients with rheumatoid arthritis. Rheumatol (Oxford), 46, 783-9.
  26. Walczak H, Miller RE, Ariail K et al (1999). Tumoricidal activity of tumor necrosis factor related apoptosis-inducing ligand in vivo. Nat Med, 5, 157-63.
  27. Woloszynska-Read A, Johnson CS, Trump DL (2011). Vitamin D and cancer: clinical aspects. Best Pract Res Clin Endocrinol Metab, 25, 605-15.
  28. Yalcin AD, Bisgin A, Kargi A et al (2012). Serum soluble TRAIL levels in patients with severe persistent allergic asthma: its relation to Omalizumab treatment. Med Sci Monit, 18, 11-15.
  29. Zhang Q, Kanterewicz B, Buch S et al (2012). CYP24 inhibition preserves 1$\alpha$,25-dihydroxyvitamin D(3) anti-proliferative signaling in lung cancer cells. Mol Cell Endocrinol, (Epub ahead of print)

Cited by

  1. Association between Laryngeal Squamous Cell Carcinoma and Polymorphisms in Tumor Necrosis Factor Related Apoptosis Induce Ligand (TRAIL), TRAIL Receptor and sTRAIL Levels vol.15, pp.24, 2015,
  2. Effect of trail C1595T variant and gene expression on the pathogenesis of non-small cell lung cancer vol.14, pp.1, 2019,